The craziest part of Musk v. Altman happened while the jury was out of the room

OpenAI-related litigation took a negative turn after Judge Yvonne Gonzalez Rogers questioned Jared Birchall over a $97.4 billion xAI-led bid for OpenAI’s nonprofit assets. Musk’s team may have opened the door to additional discovery or scrutiny around the bid, including possible anticompetitive issues, after Birchall’s testimony was struck and the judge indicated she will rule on it tomorrow. The article suggests potential legal risk for Musk, but the immediate market impact is likely limited.

Analysis

The immediate market read is not about liability dollars; it is about litigation leverage. The judge’s frustration around discovery and the apparent attempt to introduce a side issue likely increases the odds of a broader factual record that could expose internal deal logic, which is more damaging to Musk’s negotiating posture than any single adverse ruling. For AI/private-market comps, this is a governance overhang on xAI’s fundraising narrative: counterparties will price in process risk, disclosure risk, and the possibility that future financing or strategic transactions face court scrutiny.

Second-order, the most meaningful loser is not OpenAI equity value in isolation but Musk’s ability to credibly argue clean hands in any antitrust or competitive restraint dispute. If the court infers that the bid was tactical rather than bona fide, it strengthens the narrative that large strategic offers can be used as litigation weapons, which raises the cost of future M&A, tender bids, and consortium formation across private AI. That could modestly benefit incumbent public AI infrastructure beneficiaries with cleaner governance profiles and fewer transaction overhangs.

Catalyst timing is short: the next 1-5 trading days are about the judge’s ruling on the testimony, possible sanctions, and whether additional discovery is unlocked. Over 1-3 months, the larger risk is reputational contamination of xAI’s capital-raising cadence and any partnership talks that require board or regulator comfort. The contrarian take is that this may still resolve as courtroom theater rather than a substantive antitrust bomb; unless a document trail ties the bid to exclusionary conduct, the long-tail economic damage may be limited to a modest valuation discount rather than a structural impairment.

Key Decisions for Investors

• Avoid initiating fresh long exposure to private AI/venture governance-sensitive names with Musk linkage for the next 1-2 weeks; wait for the judge’s ruling before sizing risk, as a discovery expansion could reprice financing assumptions quickly.
• Relative value: long MSFT / short a basket of private-AI proxy exposure via secondary-market names if available; the trade favors incumbents with lower litigation and governance friction if AI capital formation becomes more contested.
• For public-market expression, consider a small tactical long in GOOGL or MSFT against a short in TSLA on any post-ruling strength if discovery broadens; the risk/reward is skewed toward clean-balance-sheet AI beneficiaries versus headline-sensitive allocators.
• If the court allows broader testimony/discovery, add downside hedges on TSLA via 1-3 month put spreads rather than outright short stock; this keeps theta defined while capturing a potential multiple compression from governance overhang.
• If the ruling is narrow and the testimony is effectively struck, fade any knee-jerk weakness in TSLA/xAI-related sentiment within 24-48 hours; the base case is reputational noise, not near-term cash-flow damage.